Wall Street analysts covering Aptiv have set an average one-year price target implying a potential gain of 26.6% from current levels. This aggregate forecast is based on twenty-five research firms, including four that carry a strong-buy recommendation, fourteen with buy ratings and seven with hold assessments. The mean target stands at $96.63, reflecting upgrades from Evercore ISI (from $95 to $100) and Daiwa Capital Markets (from $79 to $100) over recent months.

MarketBeat’s compilation shows Aptiv carries an average consensus rating of “Moderate Buy.” Recent individual shifts include Wall Street Zen upgrading from buy to strong-buy on December 13, Zacks Research lifting the stock from hold to strong-buy on December 9, and Weiss Ratings maintaining a hold (C-) rating on December 29. UBS raised its target from $75 to $94 in early October, while Wells Fargo trimmed its objective slightly from $100 to $99 in December.

In the third quarter ended October 30, Aptiv reported earnings per share of $2.17, beating the Zacks consensus by $0.36, on revenue of $5.21 billion versus expectations of $5.05 billion. Year-over-year, revenue rose 7.4% and EPS improved from $1.83. Net margin expanded to 1.46% and return on equity reached 18.51%. Management set full-year EPS guidance at a range of 7.55–7.85 and Q4 at 1.60–1.90; sell-side analysts forecast full-year EPS of 7.20.

Institutional ownership remains high at 94.2%. In Q3, Generali Asset Management reduced its position by 19.8%, selling 6,554 shares to hold 26,569 shares (valued at $2.29 million). By contrast, Norges Bank initiated a stake worth approximately $187.65 million in Q2. Swiss Life Asset Management increased its holding by 90.7% to 58,527 shares, and Hudson Bay Capital Management added 12.1%, boosting its position to 68,377 shares.